Research Scientist
Stony Brook University
Mount Sinai, New York, United States
Dr. Christopher E. Eyermann was born in Bethpage, New York and received a B.S. from Stony Brook University in Stony Brook, New York. He received a fellowship and completed a PhD in Molecular and Cellular Pharmacology at Stony Brook University and a postdoctoral position at Hunter College in New York City. He subsequently returned to Stony Brook University to study breast cancer, and now conducts translational research on peritoneal carcinomatosis (PC) in the laboratory of Dr. George Georgakis.
As a graduate student and postdoc, Dr. Eyermann studied how myelinating cells of the central nervous system develop and reorganize their cytoskeleton. He has been invited to present his work at the International Society for Neurochemistry, has a first-author peer reviewed journal publication, and 3 additional co-authorships in the field.
Dr. Eyermann returned to Stony Brook to study breast cancer biology in the Pathology Department under the mentorship of Dr. Evguenia Alexandrova. Here he investigated drug resistance mechanisms and the role of transcription factor p63 in animal models of HER2-posistive breast cancer. This work has resulted in three first-author journal publications.
In Dr. Georgakis’s lab, Dr. Eyermann has for the first time in the United States established a syngeneic animal model of peritoneal carcinomatosis and has been evaluating the efficacy of drug combinations in an experimental rat model of HIPEC. Additionally, Dr. Eyermann is also collaborating with radiologists at Stony Brook under the direction of Dr. Georgakis to develop radiotracers conjugated to therapeutic molecules, or “theranostics” to both detect and treat PC.
Dr. Eyermann is motivated to help patients with cancers that are difficult to treat and not well researched. He believes even small advances can make a big difference to those who need it most. Dr. Eyermann is married and enjoys life with his wife in Mt. Sinai, NY.
Sunday, February 18, 2024
8:00 AM - 8:10 AM AST